NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Article:

Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells.

Published online: 09 Aug 2019

https://www.tandfonline.com/doi/full/10.1080/20013078.2019.1648995

This work was supported by the European Research Council [ERC Advanced Glycotreat 339977]; Institute for Chemical Immunology [ICI0011]; Cancer Center Amsterdam [CCA2014-5-18]

Multi-antigenic vaccines can also comprise an undefined mix of tumour-associated antigens and neo-antigens in an autologous tumour lysate to stimulate dendritic cells [21,25,29]. An interim analysis of a current Phase III clinical trial with an autologous tumour lysate-pulsed dendritic cell vaccine (DCVax®-L) for newly diagnosed glioblastoma shows a median overall survival of the total intention to treat study population (treatment arm plus control arm) of 23.1 months [25], which suggests that the patients in the treatment arm of this trial live significantly longer than the expected 14.6 months based on the standard of care [15].